Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September5, 2017, Versartis, Inc. (the “Company”) announced the appointment of Dr.Robert Gut, M.D., Ph.D., to the position of Chief Medical Officer. On August30, 2017, Dr.Colin Hislop, M.D., relinquished his duties as Chief Medical Officer, effective September5, 2017, and will continue leading the Company’s development activities as Chief Development Officer.
About Versartis, Inc. (NASDAQ:VSAR)
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals. Versartis, Inc. (NASDAQ:VSAR) Recent Trading Information
Versartis, Inc. (NASDAQ:VSAR) closed its last trading session down -0.30 at 19.50 with 476,293 shares trading hands.